Extended Data Fig. 1: Study design and sample processing.
From: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Melanomas were induced in four genetically engineered mice (GEM) harboring the indicated genetic modifications by ultraviolet (UV) radiation or 7,12-Dimethylbenz[a]anthracene (DMBA) topical administration at postnatal day 3 and activation of CreERT2 at day 7. Fragments from each melanoma were expanded in C57BL/6 syngeneic mice and viably archived at low passage to generate a GEM-derived allograft (GDA) biobank. A cell line (CL) from each model was isolated. GDA and cell line-derived allografts (CLDA) were implanted in C57BL/6 mice and treated with CTLA-4 blocking antibody (αCTLA-4) or isotype control. GDAs, CLDAs and CLs from each model were processed in triplicates for whole exome sequencing (WES), RNA sequencing and/or histopathology.
